Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy

Alíz Nikolényi, Gabriella Uhercsák, Melinda Csenki, Sándor Hamar, Erika Csörgo, Ervin Tánczos, L. Thurzó, Thomas Brodowicz, Maria Wagnerova, Z. Kahán

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

There is a need for the selection of those breast cancers where benefit may be attained from the addition of an anthracycline to the adjuvant chemotherapy. The expression of topoisomerase II alpha (TOP2A) protein in 3 cohorts of breast cancers treated with adjuvant dose-dense anthracycline-based chemotherapy was determined retrospectively. The TOP2A status was analysed in relation with the other standard tumour features and the outcome. TOP2A IHC results were assessable in 106 patients: with a cut-off value of 15%, 48% of the tumours were classified as TOP2A-positive. The expression of TOP2A correlated with that of Ki67 (R∈=∈0.532, p∈

Original languageEnglish
Pages (from-to)61-68
Number of pages8
JournalPathology and Oncology Research
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Anthracyclines
Drug Therapy
Adjuvant Chemotherapy
Neoplasms
Proteins
Breast Neoplasms
DNA topoisomerase II alpha
Breast Cancer 3

Keywords

  • Adjuvant chemotherapy
  • Anthracyclines
  • Breast cancer
  • Dose-dense chemotherapy
  • Topoisomerase II alpha

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy. / Nikolényi, Alíz; Uhercsák, Gabriella; Csenki, Melinda; Hamar, Sándor; Csörgo, Erika; Tánczos, Ervin; Thurzó, L.; Brodowicz, Thomas; Wagnerova, Maria; Kahán, Z.

In: Pathology and Oncology Research, Vol. 18, No. 1, 01.2012, p. 61-68.

Research output: Contribution to journalArticle

Nikolényi, Alíz ; Uhercsák, Gabriella ; Csenki, Melinda ; Hamar, Sándor ; Csörgo, Erika ; Tánczos, Ervin ; Thurzó, L. ; Brodowicz, Thomas ; Wagnerova, Maria ; Kahán, Z. / Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy. In: Pathology and Oncology Research. 2012 ; Vol. 18, No. 1. pp. 61-68.
@article{ce2c2039d75e473aa63dd9b34653f6d4,
title = "Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy",
abstract = "There is a need for the selection of those breast cancers where benefit may be attained from the addition of an anthracycline to the adjuvant chemotherapy. The expression of topoisomerase II alpha (TOP2A) protein in 3 cohorts of breast cancers treated with adjuvant dose-dense anthracycline-based chemotherapy was determined retrospectively. The TOP2A status was analysed in relation with the other standard tumour features and the outcome. TOP2A IHC results were assessable in 106 patients: with a cut-off value of 15{\%}, 48{\%} of the tumours were classified as TOP2A-positive. The expression of TOP2A correlated with that of Ki67 (R∈=∈0.532, p∈",
keywords = "Adjuvant chemotherapy, Anthracyclines, Breast cancer, Dose-dense chemotherapy, Topoisomerase II alpha",
author = "Al{\'i}z Nikol{\'e}nyi and Gabriella Uhercs{\'a}k and Melinda Csenki and S{\'a}ndor Hamar and Erika Cs{\"o}rgo and Ervin T{\'a}nczos and L. Thurz{\'o} and Thomas Brodowicz and Maria Wagnerova and Z. Kah{\'a}n",
year = "2012",
month = "1",
doi = "10.1007/s12253-011-9417-4",
language = "English",
volume = "18",
pages = "61--68",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy

AU - Nikolényi, Alíz

AU - Uhercsák, Gabriella

AU - Csenki, Melinda

AU - Hamar, Sándor

AU - Csörgo, Erika

AU - Tánczos, Ervin

AU - Thurzó, L.

AU - Brodowicz, Thomas

AU - Wagnerova, Maria

AU - Kahán, Z.

PY - 2012/1

Y1 - 2012/1

N2 - There is a need for the selection of those breast cancers where benefit may be attained from the addition of an anthracycline to the adjuvant chemotherapy. The expression of topoisomerase II alpha (TOP2A) protein in 3 cohorts of breast cancers treated with adjuvant dose-dense anthracycline-based chemotherapy was determined retrospectively. The TOP2A status was analysed in relation with the other standard tumour features and the outcome. TOP2A IHC results were assessable in 106 patients: with a cut-off value of 15%, 48% of the tumours were classified as TOP2A-positive. The expression of TOP2A correlated with that of Ki67 (R∈=∈0.532, p∈

AB - There is a need for the selection of those breast cancers where benefit may be attained from the addition of an anthracycline to the adjuvant chemotherapy. The expression of topoisomerase II alpha (TOP2A) protein in 3 cohorts of breast cancers treated with adjuvant dose-dense anthracycline-based chemotherapy was determined retrospectively. The TOP2A status was analysed in relation with the other standard tumour features and the outcome. TOP2A IHC results were assessable in 106 patients: with a cut-off value of 15%, 48% of the tumours were classified as TOP2A-positive. The expression of TOP2A correlated with that of Ki67 (R∈=∈0.532, p∈

KW - Adjuvant chemotherapy

KW - Anthracyclines

KW - Breast cancer

KW - Dose-dense chemotherapy

KW - Topoisomerase II alpha

UR - http://www.scopus.com/inward/record.url?scp=84855294157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855294157&partnerID=8YFLogxK

U2 - 10.1007/s12253-011-9417-4

DO - 10.1007/s12253-011-9417-4

M3 - Article

C2 - 21681601

AN - SCOPUS:84855294157

VL - 18

SP - 61

EP - 68

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 1

ER -